Total Payments
$57,521
2024 Payments
$16,251
Companies
37
Transactions
197
Medicare Patients
4,509
Medicare Billing
$430,543
Payment Breakdown by Category
Research$45,375 (78.9%)
Food & Beverage$5,182 (9.0%)
Consulting$5,130 (8.9%)
Other$1,000.00 (1.7%)
Travel$820.58 (1.4%)
Education$13.44 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $45,375 | 16 | 78.9% |
| Food and Beverage | $5,182 | 174 | 9.0% |
| Consulting Fee | $5,130 | 1 | 8.9% |
| Honoraria | $1,000 | 2 | 1.7% |
| Travel and Lodging | $820.58 | 3 | 1.4% |
| Education | $13.44 | 1 | 0.0% |
Payments by Type
Research
$45,375
16 transactions
General
$12,146
181 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurent Medical Limited | $45,440 | 17 | $0 (2024) |
| Genentech USA, Inc. | $6,261 | 6 | $0 (2020) |
| Phadia US Inc. | $1,111 | 6 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $508.86 | 16 | $0 (2024) |
| ABBVIE INC. | $508.68 | 31 | $0 (2024) |
| Stryker Corporation | $455.50 | 8 | $0 (2023) |
| GENZYME CORPORATION | $400.84 | 17 | $0 (2024) |
| GlaxoSmithKline, LLC. | $371.94 | 11 | $0 (2024) |
| ALK-Abello, Inc | $283.54 | 16 | $0 (2023) |
| DUSA Pharmaceuticals, Inc. | $280.01 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,251 | 45 | Neurent Medical Limited ($15,435) |
| 2023 | $31,057 | 47 | Neurent Medical Limited ($30,005) |
| 2022 | $569.01 | 27 | GlaxoSmithKline, LLC. ($151.49) |
| 2021 | $757.75 | 18 | Biohaven Pharmaceuticals, Inc. ($247.54) |
| 2020 | $6,349 | 10 | Genentech USA, Inc. ($6,243) |
| 2019 | $526.19 | 14 | Intersect ENT, Inc. ($193.31) |
| 2018 | $233.57 | 13 | AstraZeneca Pharmaceuticals LP ($48.29) |
| 2017 | $1,777 | 23 | Phadia US Inc. ($1,074) |
All Payment Transactions
197 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Neurent Medical Limited | NEUROMARK Device (Device), NEUROMARK Radiofrequency Console | — | Cash or cash equivalent | $480.00 | Research |
| Study: Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) • Category: Electrosurgical, Cutting & Coagulation & Accessories | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/13/2024 | AERIN MEDICAL INC. | VIVAER STYLUS (Device), RHINAER STYLUS | Food and Beverage | In-kind items and services | $32.33 | General |
| Category: EAR NOSE & THROAT | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: IMMUNOLOGY | ||||||
| 10/15/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: Immunology | ||||||
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/05/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $28.15 | General |
| Category: NEUROSCIENCE | ||||||
| 09/03/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $25.48 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 08/27/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: PAIN | ||||||
| 08/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/01/2024 | kaleo, Inc. | AUVI-Q (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Allergy | ||||||
| 07/30/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/22/2024 | Neurent Medical Limited | NEUROMARK Device (Device), NEUROMARK Radiofrequency Console | — | Cash or cash equivalent | $1,325.00 | Research |
| Study: NEUROMARK Randomized Controlled Trial • Category: Electrosurgical, Cutting & Coagulation & Accessories | ||||||
| 07/22/2024 | Neurent Medical Limited | NEUROMARK Device (Device), NEUROMARK Radiofrequency Console | — | Cash or cash equivalent | $90.00 | Research |
| Study: Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) • Category: Electrosurgical, Cutting & Coagulation & Accessories | ||||||
| 06/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: Immunology | ||||||
| 06/13/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $26.58 | General |
| Category: NEUROSCIENCE | ||||||
| 05/31/2024 | Neurent Medical Limited | NEUROMARK Device (Device), NEUROMARK Radiofrequency Console | — | Cash or cash equivalent | $2,475.00 | Research |
| Study: NEUROMARK Randomized Controlled Trial • Category: Electrosurgical, Cutting & Coagulation & Accessories | ||||||
| 05/30/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 05/23/2024 | Phadia US Inc. | ImmunoCAP (Device) | Food and Beverage | Cash or cash equivalent | $18.21 | General |
| Category: Allergy/Immunology | ||||||
| 05/23/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: IMMUNOLOGY | ||||||
| 05/15/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/02/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Education | In-kind items and services | $13.44 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 04/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: Immunology | ||||||
| 04/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: PAIN | ||||||
| 04/10/2024 | Neurent Medical Limited | NEUROMARK Device (Device), NEUROMARK Radiofrequency Console | — | Cash or cash equivalent | $450.00 | Research |
| Study: Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) • Category: Electrosurgical, Cutting & Coagulation & Accessories | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NEUROMARK Randomized Controlled Trial | Neurent Medical Limited | $28,050 | 7 |
| Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON) | Neurent Medical Limited | $13,380 | 6 |
| Nexus Study - Clinical Exploration of NEUROMARK System in Subjects With Chronic Rhinosinusitis (CRS) | Neurent Medical Limited | $3,945 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,913 | 3,082 | $391,105 | $192,053 |
| 2022 | 18 | 1,313 | 2,101 | $212,615 | $110,050 |
| 2021 | 17 | 754 | 864 | $140,695 | $73,476 |
| 2020 | 12 | 529 | 706 | $126,005 | $54,964 |
Total Patients
4,509
Total Services
6,753
Medicare Billing
$430,543
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 409 | 663 | $59,670 | $42,198 | 70.7% |
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2023 | 141 | 212 | $63,600 | $30,256 | 47.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 234 | 234 | $29,250 | $18,217 | 62.3% |
| 31295 | Dilation of nasal sinus using an endoscope | Office | 2023 | 11 | 11 | $48,000 | $17,579 | 36.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 140 | 181 | $25,450 | $17,034 | 66.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 115 | 115 | $28,750 | $14,082 | 49.0% |
| 92557 | Comprehensive hearing and speech recognition test | Office | 2023 | 266 | 294 | $26,460 | $8,127 | 30.7% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 15 | 690 | $13,800 | $7,504 | 54.4% |
| 31575 | Diagnostic exam of voice box using a flexible endoscope | Office | 2023 | 62 | 74 | $22,200 | $7,248 | 32.6% |
| 70486 | Ct scan of face without contrast | Office | 2023 | 58 | 62 | $15,500 | $6,126 | 39.5% |
| G0268 | Removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing | Office | 2023 | 134 | 166 | $13,275 | $5,521 | 41.6% |
| 31237 | Biopsy or removal of nasal polyp or tissue using an endoscope | Office | 2023 | 11 | 20 | $12,000 | $3,988 | 33.2% |
| 69433 | Incision of eardrum with insertion of eardrum tube under local or topical anesthesia | Office | 2023 | 14 | 16 | $5,700 | $2,771 | 48.6% |
| 30901 | Simple control of nose bleed | Office | 2023 | 15 | 23 | $9,200 | $2,746 | 29.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 56 | 61 | $5,490 | $2,564 | 46.7% |
| 92567 | Test to assess middle ear function | Office | 2023 | 91 | 110 | $2,200 | $1,392 | 63.3% |
| 92556 | Test for ability to detect and repeat spoken words with speech recognition | Office | 2023 | 41 | 41 | $2,460 | $1,312 | 53.3% |
| 95992 | Repositioning exercises of head for treatment of dizziness, each day | Office | 2023 | 26 | 33 | $2,640 | $1,131 | 42.8% |
| 92552 | Test for hearing various pitches using earphone | Office | 2023 | 41 | 41 | $2,460 | $1,096 | 44.5% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 18 | 20 | $1,500 | $712.31 | 47.5% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 15 | 15 | $1,500 | $450.06 | 30.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 281 | 373 | $33,570 | $25,096 | 74.8% |
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2022 | 91 | 122 | $36,600 | $17,910 | 48.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 165 | 165 | $20,625 | $14,041 | 68.1% |
| G0268 | Removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing | Office | 2022 | 201 | 224 | $21,000 | $8,663 | 41.3% |
About Dr. Michael Armstrong, M.D
Dr. Michael Armstrong, M.D is a Pediatric Otolaryngology healthcare provider based in Richmond, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174608053.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Armstrong, M.D has received a total of $57,521 in payments from pharmaceutical and medical device companies, with $16,251 received in 2024. These payments were reported across 197 transactions from 37 companies. The most common payment nature is "" ($45,375).
As a Medicare-enrolled provider, Armstrong has provided services to 4,509 Medicare beneficiaries, totaling 6,753 services with total Medicare billing of $430,543. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Otolaryngology
- Other Specialties Otolaryngic Allergy, Otolaryngology/Facial Plastic Surgery
- Location Richmond, VA
- Active Since 10/26/2006
- Last Updated 08/11/2010
- Taxonomy Code 207YP0228X
- Entity Type Individual
- NPI Number 1174608053
Products in Payments
- NEUROMARK Device (Device) $45,440
- Xolair (Biological) $6,261
- ImmunoCAP (Device) $1,111
- DUPIXENT (Biological) $909.70
- NURTEC ODT (Drug) $378.05
- NUCALA (Biological) $371.94
- Odomzo (Drug) $280.01
- QULIPTA (Drug) $222.29
- Odactra (Drug) $187.00
- UBRELVY (Drug) $176.79
- CardioMEMS HF System (Device) $153.85
- SCOPIS ENT (Device) $152.53
- CLARIFIX (Device) $144.05
- Latera (Device) $130.72
- PROPEL (Device) $129.80
- BOTOX (Biological) $124.58
- SINUVA (Drug) $115.31
- Micra (Device) $104.60
- AUVI-Q (Drug) $95.82
- XprESS Multi-Sinus Dilation System (Device) $71.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.